Related Experiment Video
Updated: Jul 7, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Alpha-MSH promotes spontaneous post-ischemic pneumonia in mice via melanocortin-receptor-1
Olaf Schulte-Herbrüggen1, David Quarcoo, Thomas Brzoska
1Department of Psychiatry, Charité Universitaetsmedizin Berlin, Germany.
Abstract:
Pneumonia constitutes a serious medical complication and major cause of death in patients after cerebral stroke. In a mouse model of cerebral ischemia (MCAO), we have recently demonstrated that stroke animals spontaneously develop severe bacterial pneumonia which is preceded by a stress-mediated suppression of cellular immune responses in primary and secondary lymphoid organs. However, little is known about the mechanisms leading to impaired pulmonary antimicrobial immune response after cerebral ischemia. In this study, we demonstrate a rapid up-regulation of the immunomodulatory neuropeptide alpha-melanocyte-stimulating hormone (MSH) in the lung within 24 h after cerebral ischemia. Systemic administration of the naturally occurring alpha-MSH receptor-1 (MC-1R) antagonist agouti immediately after MCAO significantly reduced pulmonary bacterial burden at 72 h. In contrast, administration of recombinant alpha-MSH further increased bacterial load in lungs of MCAO animals. In addition, cerebral ischemia resulted in a strong modulation of local pulmonary immunity with increased production of IL-10 by lung macrophages, reduced pulmonary lymphocyte counts, as well as decreased lymphocytic IFN-gamma but increased IL-4 production. However, alpha-MSH blockade by administration of agouti did not prevent changes in lung immune cell numbers or cytokine production suggesting that suppression of cellular immune responses is not the primary mechanism of alpha-MSH mediated inhibition of pulmonary antibacterial defenses. This study indicates an important role of alpha-MSH for the increased infectious susceptibility after cerebral ischemia and may provide new therapeutic strategies to prevent post-stroke infectious complications.
Insights
Stroke-induced pneumonia is worsened by alpha-melanocyte-stimulating hormone (MSH). Blocking MSH reduces lung bacteria after stroke, suggesting a new therapeutic target for post-stroke infections.
Area of Science:
- Immunology
- Neuroscience
- Pathology
Background:
- Pneumonia is a significant cause of mortality post-cerebral stroke.
- Stroke triggers immune suppression, increasing pneumonia risk.
- Mechanisms of impaired lung immunity after stroke are poorly understood.
Purpose of the Study:
- Investigate the role of alpha-melanocyte-stimulating hormone (MSH) in post-stroke pneumonia.
- Determine if MSH blockade can mitigate lung bacterial burden after cerebral ischemia.
Main Methods:
- Utilized a mouse model of cerebral ischemia (MCAO).
- Administered alpha-MSH receptor-1 (MC-1R) antagonist (agouti) or recombinant alpha-MSH.
- Assessed pulmonary bacterial load, immune cell counts, and cytokine production (IL-10, IFN-gamma, IL-4).
Main Results:
- Alpha-MSH rapidly increased in the lung post-ischemia.
- Agouti administration reduced lung bacterial burden.
- Alpha-MSH administration increased bacterial load; immune cell and cytokine changes were not prevented by agouti.
Conclusions:
- Alpha-MSH plays a key role in increased susceptibility to infection after cerebral ischemia.
- Alpha-MSH blockade offers a potential therapeutic strategy for preventing post-stroke infections.
- The mechanism of MSH-mediated immune suppression in the lung may not involve direct modulation of immune cell counts or cytokine profiles.

